Success Stories

Fotolia_107419345_Sm

BIRAD's professional team has earned the trust of both BIU faculty and industry partners seeking to move Bar-Ilan-based initiatives from the lab into the marketplace.

The following is a selection of just some of the startup companies launched by BIRAD over the past few years.

PHINERGY
CONTINUSE BIOMETRICS
GRIDON
DYADIC
SIRT LAB
NANOSONO
Z-SQUARE
XL Therapeutics
PHINERGY

Phinergy is a leading developer of breakthrough zero-emission, high energy-density systems based on metal-air energy technologies resulting from discoveries  stemming from the  the laboratory of Prof. Arie Zaban.

The company’s primary focus is on aluminum-air and zinc-air batteries. Unlike conventional batteries that carry oxygen, these batteries freely breathe oxygen from the ambient air to release the energy contained in metals.

Phinergy's technologies offer significant advantages including:

  • Ultra High energy density
  • Zero CO2 emissions
  • Fully recyclable materials
  • Safety
  • Competitive cost

Phinergy's Aluminum-Air battery system has been successfully integrated into an electric vehicle resulting in more than three times the driving range of current EVs. Phinergy is currently partnering with French automobile manufacturer Renault to integrate its aluminum-air batteries in mass-production, long-range Electric Vehicles, as well as with US-based aluminum giant Alcoa, who will be providing materials for the batteries themselves.

CONTINUSE BIOMETRICS

ContinUse Biometrics was established based on years of research work in the laboratory of Prof. Zeev Zalevsky, a leader in the field of photonics and electro optics.

ContinUse Biometrics develops a unified biometric sensor platform for mobile, Internet of Things & consumer devices. It is based on remote, contactless, active and continuous biometrics scanning. The system actively and continuously measures biomedical parameters, providing authentication and bio-competence information of individuals. The sensor/platform is capable of measuring various bio-parameters simultaneously for health and wellness monitoring.

ContinUse Biometrics uniquely identifies a person's physical and behavioral characteristics. Biometrics is expected to play a major role, both as an enabler and as a standalone solution, in various domains including access & tracking control; digital, mobile, social & personal applications; retail & shopping; as well as Internet of Things. The global biometrics market is expected to triple its value by 2019 and reach an estimated $16.7 billion.

GRIDON

GridON is an energy technology company based on discoveries made in the laboratory of Prof. Yosef Yeshurun

GridOn produces commercial Fault Current Limiters for power distribution and transmission networks. Based on combining industry-standard, proven transformer technology with a unique, proprietary concept that uses magnetic flux alteration to trigger instant response to a fault and prevent power outages, GridON's solution improves grid resilience and reliability, extends the useful life of network assets, and could cut capital expenditure by tens to hundreds of millions of dollars per customer.

Currently partnering with Australian based Wilson Transformer Company to bring its product line to market, GridON has won a number of prizes, including the 2013 UK Energy Innovation Award, the 2012 ACES Smart Grid award, and the "Ecomagination Challenge" – presented by energy giant General Electric as one of the top five energy-related innovations of 2011.

GridON’s 30MVA Fault Current Limiter (FCL) has been commissioned and energized onto a live network at one of Western Power Distribution’s primary substations in Birmingham, UK, in early April 2015. GridON designed and built its novel FCL within five months of contract signature, before testing and then installing it onto the live grid. Another GridON FCL is already installed at a different utility operator’s substation since early 2013 and has proven very effective limiting numerous faults of all types during the past two years; performing exactly as was specified and designed for. These two live installations in the UK prove the maturity of GridON’s product and its extensive capabilities.

DYADIC

Dyadic Security incorporated in 2014, based on the research work on the secure multiparty computation of  Prof. Yehuda Lindell.

Dyadic's Distributed Security Module (DSM) provides protection by removing the security single point of failure caused by holding keys and credentials in one place where they are vulnerable. Dyadic’s DSM randomly splits keys and credentials across servers so that they are never in any single place to be stolen. Dyadic's breakthrough technology carries out cryptographic operations and authentication without bringing the key parts together.

The resilience of Dyadic’s solution to hacking was rigorously, and independently, tested by Risk Factory UK. Risk Factory specializes in high profile risk assessment and vulnerability testing. The result of their penetration test, in which they were given access to all servers but one, is summarized as follows:

“The DSM was found to be a robust security product and it was not possible during testing to compromise the encryption keys or decrypt any encrypted data stored in the database.”.

Minimal invasive diagnostic and therapeutic procedures are now a matter of routine and are undergoing continual development. There is a growing need for these procedures to be even micro-invasive. Z-square is developing an advanced technology platform involving various elements for complete imaging and treatment. The latter may include various energy/drug delivery, irrigation, and tissue handling. Z-square`s technology is based on a proprietary multi-functional microendoscope device, capable of high-quality imaging within a super-slim fiber, integrated with treatment capabilities based on discoveries made in the laboratory of BIU Prof. Zeev Zalevsky. While the currently used endoscopes often provide limited optics with cumbersome workflow, are expensive and fragile, Z-square can provide efficient and cost-effective solutions. It is estimated that approximately 2.5 million minimally invasive procedures performed in the U.S. every year.

SIRT LAB

SirtLab is  developimg drugs aimed at metabolic diseases  based on discoveries made in the laboratory of BIU Prof. Chaim Cohen.

SirTLab Corporation's goal is to cure age-related diseases and extend healthy lifespan

based on its breakthrough treatment methods that activate the gene SIRT6 on the

cellular level.

SirTLab is currently developing the following four effective and practical

ways of treatment with SIRT6):

  1. Small Molecules – This treatment involves a small molecule that activates SIRT6

on the cellular level.

  1. Nano-Technology Anti-miR – Based on granted patent of the Company, the treatment here is targeted delivery of small RNA molecules that shutdown the negative regulators of SIRT6 (micro-RNAs).
  2. Food grade Herbal additives – Screening of natural and herbal drugs for activation of Sirt6 in order to create quick treatment of activating Sirt6.
NANOSONO

NSC-NanoSono Cooperation, based on technology developed by Prof Gedanken.

NSC-NanoSono Cooperation, based on technology developed by Prof Gedanken, has an innovative coating technology that can transform almost any medical device, disposable fabricor  filters using one step process to achieve a long term antibacterial and antibiofilm properties, NanoSono , in collaboration with two commercial companies, is currently building two production sites for production of antibacterial catheters and bandages.

Z-SQUARE

Z-square`s technology is based on a proprietary multi-functional microendoscope device, capable of high quality imaging within a super-slim fiber, integrated with treatment capabilities  stemming from  the laboratory of Prof. Zeev Zalevsky.

Minimal invasive diagnostic and therapeutic procedures are now a matter of routine and are undergoing continual development. There is a growing need for these procedures to be even micro-invasive. Z-square is developing an advanced technology platform involving various elements for complete imaging and treatment. The latter may include various energy / drug delivery, irrigation and tissue handling. While the currently used endoscopes often provide limited optics with cumbersome workflow, are expensive and fragile, Z-square can provide efficient and cost effective solutions. It is estimated that approximately 2.5 million minimally invasive procedures performed in the U.S. every year.

For More Information

XL Therapeutics

Dr. Rachel Eren

XL Therapeutics is a biopharmaceutical company aiming to develop small molecule compounds (SMCs) to treat patients suffering from Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT), rare primary human immunodeficiencies that are caused by the absence or suboptimal function of the WAS protein (WASp).

XL Therapeutics was established in the FutuRx incubator in May 2016.

Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT)

WAS is caused by a defect in an X-chromosome-linked gene encoding WASp. WASp, an adaptor protein expressed exclusively in hematopoietic cells, is essential for normal hematopoietic cell function, and its deficiencies lead to defects in proliferation, migration and overall activation of immune cells. The function of many hematopoietic lineages is affected by WASp deficiency. The more severe defects in WASp expression lead to WAS which includes varying degrees of thrombocytopenia, eczema, immunodeficiency, autoimmunity, and malignancy. Less severe deficiencies in protein expression can lead to XLT where the primary defects are manifested in platelet dysfunction. WAS and XLT each affect about 4 patients per million male newborns worldwide, and most WAS patients die by the age of 10 without early intervention.

 SCIENTIFIC APPROACH

Protecting WASp from degradation in WAS/XLT patients could restore normal or near-normal protein levels and thus improve immune cell function.

XL Therapeutics has identified SMCs that bind to WASp and stabilize the protein by protecting it from ubiquitylation and proteasomal degradation. These WASp-binding SMCs will undergo further development to provide a lead SMC with drugable properties and acceptable safety profile, that would present a potential novel treatment for WAS/XLT patients wherein the molecular defect in WASp affects protein stability.